Perfect PERF Q1 2026 Earnings Surprise EPS 002 Up Significant Oakland Housing Market Faces Steep Price Declines Amid National Trends Pixel Launch Raises Privacy Flags Google Assistants AI Under Scrutiny BP Joins Forces with SOCAR and Uzbekneftegaz for Uzbek Gas Exploration Anthropic Takes on Pentagon in Court Over Blacklisting as Supply Chain Risk DHT Holdings DHT Posts Q1 2026 Earnings Beat Heres What Drove It Why Verra VRRM Just Dropped 094 What to Watch 20260521 US Advocacy Groups Call for Probe into Robloxs Child Safety Measures and InGame Spending Elon Musks X Fined A650000 by Australian Court for Child Protection Law Breaches Gujarat and Tamil Nadu Partner to Establish Shared Technical Facilities for Space Manufacturing Boost Duke Energy DUK Faces Reduced Analyst Price Target Amid Utility Sector Headwinds US Stocks Open Higher as AI Momentum and Mideast Truce Hopes Boost Sentiment 1100 Architect Named to Forbes Americas Top Architects 2025 Expands Bold Presence Near Boston Kazatomprom Production Surges 17 in Q3 Bolstering Global Uranium Supply ERII Q1 2026 Earnings EPS Miss Highlights Ongoing Cost Pressures Despite Stock Gain SSSSL Q1 2026 Earnings Massive EPS Surprise on Investment Gains Bond Price Edges Lower Murphy USA Inc MUSA Q1 2026 Earnings Earnings Surge Past Estimates Stock Slips Marginally MG Q1 2026 Earnings EPS Beats Estimates by 553 as Company Reports Profitability PrimeEnergy Resources PNRG Q4 2025 Earnings Profitability Holds Firm with EPS of 143 Stock Advances 454 Citius Oncol CTOR Q1 2026 Earnings Miss EPS 143 vs 001 Expected Ambarella AMBA Edges Higher as Resistance Level Nears PTC Therapeutics PTCT Q1 2026 Beat Revenue NA EPS Exceeds by Significant Jeff Bezos Defends Billionaires Promotes AI and Proposes Tax Reform in CNBC Interview MBINL Q1 2026 Earnings EPS Surpasses Estimates Shares Edge Higher Dolby DLB Stock Analysis 141 Gain What to Watch 20260520 Supermarkets Resist Calls for Mandatory Price Caps on Milk Bread and Eggs as Government Confirms Talks EVGN Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Continues RD Spend